Trials / Recruiting
RecruitingNCT07100249
A Study of HDM2012 in Patients With Advanced Solid Tumor
A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of HDM2012 in Subjects With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 129 (estimated)
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug HDM2012 in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HDM2012 | HDM2012 will be administered via IV infusion. |
Timeline
- Start date
- 2025-08-06
- Primary completion
- 2027-10-01
- Completion
- 2028-06-01
- First posted
- 2025-08-03
- Last updated
- 2025-08-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07100249. Inclusion in this directory is not an endorsement.